Sarepta Therapeutics Inc (BSP:S1RP34)
R$ 37.72 -0.52 (-1.36%) Market Cap: 72.06 Bil Enterprise Value: 73.29 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 79/100

Sarepta Therapeutics Inc Update Call Transcript

Oct 30, 2023 / 08:30PM GMT
Release Date Price: R$29.75
Operator

Good day, and thank you for standing by. Welcome to the Sarepta Therapeutics Update Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Douglas Ingram, President and CEO.

Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director

Thank you, Josh. Good afternoon, everyone, and thank you for joining Sarepta Therapeutics call to review the top line results for EMBARK. Our double-blind, placebo-controlled study intended to confirm the benefits of ELEVIDYS in children with Duchenne. Next slide, please. We will very likely make some predictions about the future or other forward-looking statements this evening. I would ask you to please review our public filings for the various risks and uncertainties that come with those sort of forward-looking statements.

Next slide. In a moment, Dr. Rodino-Klapac will review the results and our path forward. But let me summarize at least our perspective on them now. Our perspective is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot